Lori Anderson v. K-V Pharmaceutical Company, 791 F.3d 915

Background

K-V Pharmaceutical acquired rights to a drug (rebranded Makena) and obtained FDA orphan-drug exclusivity on Feb. 3, 2011; Makena launch was critical to K-V’s survival.
On Feb. 14, 2011 K-V held an investor call and filed an 8-K that included forward-looking statements about the planned Makena launch, pricing ($1,500 per injection), expected insurer coverage, and a financial-assistance program; the 8-K incorporated risk disclosures from the Form 10-K.
Plaintiffs (shareholders who bought between Feb. 14 and Apr. 4, 2011) allege the company and officers made materially false/misleading statements and omissions about FDA enforcement of exclusivity, insurer coverage, and the adequacy of the assistance program; allegations relied on four confidential witnesses.
After pricing was announced, public backlash and FDA statements followed: FDA said it would not enforce against pharmacies compounding the equivalent of Makena; K-V later reduced price to $690; K-V stock fell sharply.
District court dismissed under Fed. R. Civ. P. 12(b)(6), finding challenged statements were PSLRA-protected forward-looking statements with meaningful cautionary language and therefore not actionable; court also found plaintiffs failed to plead scienter and denied reconsideration to expand leave to amend regarding confidential-witness allegations.

Issues

Issue	Plaintiff's Argument	Defendant's Argument	Held
Whether K-V’s statements about FDA enforcement/exclusivity were forward-looking and covered by PSLRA safe harbor	Statements were not truly forward-looking and lacked meaningful cautionary language; plaintiffs’ confidential witnesses show K-V knew FDA wouldn’t enforce exclusivity	Statements were forward-looking or assumptions about future enforcement and were accompanied by meaningful, company-specific cautionary language (Form 10-K incorporated)	Court: Statements are forward-looking, accompanied by meaningful cautionary language, and fall within PSLRA safe harbor—not actionable
Whether plaintiffs adequately pleaded scienter as required by PSLRA	Confidential witnesses provided detailed facts showing K-V knew or should have known FDA would not enforce exclusivity	Plaintiffs failed to plead a strong inference of scienter; safe-harbor resolution makes scienter unnecessary to decide	Court: Because statements fall in the safe harbor, it did not reach scienter; dismissal affirmed
Whether the Feb. 17 letter to compounding pharmacies is actionable in securities fraud	Letter showed K-V knowingly misrepresented enforcement risk and was a basis for securities claims	Letter was not made in connection with the purchase/sale of securities and thus not actionable under securities laws	Court: Letter not used in connection with securities transactions; not actionable
Whether district court abused discretion by denying plaintiffs’ motion for reconsideration to expand leave to amend (confidential witnesses)	Plaintiffs identified purportedly new CW facts that would cure pleading defects and merit leave to amend	District court correctly treated the motion as seeking to raise facts available earlier; plaintiffs had opportunity to present them earlier	Court: No abuse of discretion—motion for reconsideration not vehicle for new evidence; denial affirmed

Key Cases Cited

McCrary v. Stifel, Nicolaus & Co., Inc., 687 F.3d 1052 (8th Cir. 2012) (PSLRA heightened pleading and scienter standards for securities claims)
Ferris, Baker Watts, Inc. v. Ernst & Young, LLP, 395 F.3d 851 (8th Cir. 2005) (elements required to state a securities fraud claim under §10(b)/Rule 10b–5)
Horizon Asset Mgmt. Inc. v. H & R Block, Inc., 580 F.3d 755 (8th Cir. 2009) (loss causation and Rule 10b–5 principles)
In re Aetna, Inc. Sec. Litig., 617 F.3d 272 (3d Cir. 2010) (meaningful cautionary language requirement under PSLRA)
Southland Sec. Corp. v. INSpire Ins. Solutions, Inc., 365 F.3d 353 (5th Cir. 2004) (‘meaningful’ cautionary language requires company-specific risk disclosures)
Harris v. Ivax Corp., 182 F.3d 799 (11th Cir. 1999) (test for whether a statement is forward-looking focuses on when truth/falsity can be determined)
W. Wash. Laborers-Emp’rs Pension Trust v. Panera Bread Co., 697 F. Supp. 2d 1081 (E.D. Mo. 2010) (forward-looking-statement analysis)
Popoalii v. Correctional Med. Servs., 512 F.3d 488 (8th Cir. 2008) (standards for abuse of discretion in denial of leave to amend)
Auto Servs. Co., Inc. v. KPMG, LLP, 537 F.3d 853 (8th Cir. 2008) (Rule 54(b) and when district court may revise interlocutory decisions)